Trial Information

Summary: A Treatment of Unresectable Hepatocellular Carcinoma with TheraSphere (Yittrium-90 Glass Microspheres): A HDE Treatment Use Protocol

You have been asked to be treated using TheraSphereŽ because you have a cancer of the liver (hepatoma).  Surgical removal of the tumor is not possible because of the location and/or extent of your tumor.  The purpose of this protocol is to provide access to TheraSphereŽ treatment to subjects with liver cancer who cannot be treated by surgical removal of the tumor.  Information will be collected for research purposes about response to treatment and side effects.  Your treatment and active monitoring on this  is expected to last 30 days for each treatment you receive.  After your treatment on this  is over, your medical condition will be followed on this  for up to two years.   

Patient Inclusion/Exclusion Criteria:

- See http://clinicaltrials.coh.org for additional information.

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: July 7, 2008 at 2:41:11 PM